drugset
drugset / Trial / NCT05255458

A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia

NCT05255458 ↗

Phase 3 Completed 122 enrolled Akeso
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled phase 3 clinical study evaluating the long-term efficacy and safety of AK102 in patients with primary hypercholesterolemia and mixed hyperlipidemia.

Timeline

Start
2021-11-04
Primary completion
2023-01-09
Completion
2023-01-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AK102 Monoclonal antibody — Subcutaneous

Indications

hyperlipidemia